{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:59:04Z","timestamp":1774594744731,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The interactions of antibodies with myeloid Fc\u03b3 receptors and the complement system are regulated by an Asn297-linked glycan in the Fc portion of IgG. Alterations of serum IgG-Fc glycosylation have been reported in various autoimmune diseases, and correlate with treatment response and disease activity. We hypothesized that IgG-Fc glycosylation is altered in immune thrombocytopenia (ITP) and associates with response to anti-CD20 monoclonal antibody treatment (rituximab). IgG-Fc glycosylation was analyzed by liquid chromatography-mass spectrometry. We found that IgG-Fc glycosylation was identical between refractory ITP patients (HOVON64 trial; N\u2009=\u2009108) and healthy controls (N\u2009=\u2009120). Two months after rituximab treatment, we observed a shift in Fc glycosylation, with a mean 1.7% reduction in galactosylation for IgG1 and IgG4 and a mean 1.5% increase for bisection in IgG1, IgG2\/3 and IgG4 (adjusted p\u2009&lt;\u20091.7\u2009\u00d7\u200910<jats:sup>\u22123<\/jats:sup> and p\u2009&lt;\u20092\u2009\u00d7\u200910<jats:sup>\u22124<\/jats:sup>, respectively). Neither baseline nor longitudinal changes in IgG-Fc glycosylation after rituximab were associated with clinical treatment response. We conclude that IgG-Fc glycosylation in refractory ITP is similar to healthy controls and does not predict treatment responses to rituximab. The observed changes two months after treatment suggest that rituximab may influence total serum IgG-Fc glycosylation. Overall, our study suggests that the pathophysiology of refractory ITP may differ from other autoimmune diseases.<\/jats:p>","DOI":"10.1038\/s41598-020-59651-7","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T11:03:11Z","timestamp":1582196591000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["IgG-Fc glycosylation before and after rituximab treatment in immune thrombocytopenia"],"prefix":"10.1038","volume":"10","author":[{"given":"David E.","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noortje","family":"de Haan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myrthe E.","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leendert","family":"Porcelijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Ellen","family":"van der Schoot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masja","family":"de Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaap-Jan","family":"Zwaginga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Wuhrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gestur","family":"Vidarsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"key":"59651_CR1","unstructured":"Porcelijn, L. et al. Detection of platelet autoantibodies to identify immune thrombocytopenia: state of the art. British Journal of Haematology. 39(Suppl. 1), 195 (2018 May 29)."},{"key":"59651_CR2","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","volume":"117","author":"C Neunert","year":"2011","unstructured":"Neunert, C. et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 117, 4190\u2013207 (2011).","journal-title":"Blood."},{"key":"59651_CR3","doi-asserted-by":"crossref","unstructured":"Patel, V.L. et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. American Society of Hematology; 119(25), 5989\u201395 (2012 Jun 21).","DOI":"10.1182\/blood-2011-11-393975"},{"key":"59651_CR4","doi-asserted-by":"crossref","unstructured":"Godeau, B. & Stasi R. Is B-cell depletion still a good strategy for treating immune thrombocytopenia? La Presse Medicale. Elsevier Masson SAS; 43(4), e79\u2013e85 (2014 Apr 1).","DOI":"10.1016\/j.lpm.2014.01.011"},{"key":"59651_CR5","unstructured":"Porcelijn, L. et al. Lack of detectable platelet autoantibodies is correlated with non-responsiveness to rituximab treatment in ITP patients. Blood. blood\u20132016\u201311\u2013751719\u20139 (2017 May 3)."},{"key":"59651_CR6","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3389\/fimmu.2017.00877","volume":"8","author":"G Dekkers","year":"2017","unstructured":"Dekkers, G. et al. Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities. Front Immunol. 8, 877 (2017).","journal-title":"Front Immunol."},{"key":"59651_CR7","doi-asserted-by":"crossref","unstructured":"Parekh, R. B. et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature. 316(6027), 452\u20137 (1985 Aug).","DOI":"10.1038\/316452a0"},{"key":"59651_CR8","doi-asserted-by":"crossref","unstructured":"Tomana, M., Schrohenloher, R. E., Koopman, W. J., Alarc\u00f3n, G. S. & Paul, W. A. Abnormal glycosylation of serum IgG from patients with chronic inflammatory diseases. Arthritis Rheum. 31(3), 333\u20138 (1988 Mar).","DOI":"10.1002\/art.1780310304"},{"key":"59651_CR9","doi-asserted-by":"crossref","unstructured":"Sonneveld, M. E. et al. Patients with IgG1-anti-red blood cell autoantibodies show aberrant Fc-glycosylation. Sci Rep. 7(1), 8187 (2017 Aug 15).","DOI":"10.1038\/s41598-017-08654-y"},{"key":"59651_CR10","doi-asserted-by":"crossref","unstructured":"Vu\u010dkovi\u0107, F. et al. Association of systemic lupus erythematosus with decreased immunosuppressive potential of the IgG glycome. Arthritis Rheumatol. Wiley-Blackwell; 67(11), 2978\u201389 (2015 Nov).","DOI":"10.1002\/art.39273"},{"key":"59651_CR11","doi-asserted-by":"crossref","unstructured":"Fokkink, W.-J. R. et al. IgG Fc N-glycosylation in Guillain-Barr\u00e9 syndrome treated with immunoglobulins. J. Proteome. Res. American Chemical Society; 13(3), 1722\u201330 (2014 Mar 7).","DOI":"10.1021\/pr401213z"},{"key":"59651_CR12","doi-asserted-by":"crossref","unstructured":"Holland, M. et al. Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis. Biochim Biophys Acta. 1760(4), 669\u201377 (2006 Apr).","DOI":"10.1016\/j.bbagen.2005.11.021"},{"key":"59651_CR13","doi-asserted-by":"crossref","unstructured":"Wuhrer, M. et al. Skewed Fc glycosylation profiles of anti-proteinase 3 immunoglobulin G1 autoantibodies from granulomatosis with polyangiitis patients show low levels of bisection, galactosylation, and sialylation. J. Proteome. Res. 14(4), 1657\u201365 (2015 Apr 3).","DOI":"10.1021\/pr500780a"},{"key":"59651_CR14","doi-asserted-by":"crossref","unstructured":"\u0160imurina, M. et al. Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases. Gastroenterology. 154(5), 1320\u20131333.e10 (2018 Apr).","DOI":"10.1053\/j.gastro.2018.01.002"},{"key":"59651_CR15","unstructured":"Lauc, G. et al. Loci Associated with N-Glycosylation of Human Immunoglobulin G Show Pleiotropy with Autoimmune Diseases and Haematological Cancers. Gibson G, editor. PLoS Genet. 9(1), e1003225\u201317 (2013 Jan 31)."},{"key":"59651_CR16","doi-asserted-by":"crossref","unstructured":"Bondt, A. et al. ACPA IgG galactosylation associates with disease activity in pregnant patients with rheumatoid arthritis. Ann. Rheum. Dis; annrheumdis\u20132018\u2013212946 (2018 Apr 3).","DOI":"10.1136\/annrheumdis-2018-212946"},{"key":"59651_CR17","doi-asserted-by":"crossref","unstructured":"Parekh, R. B. et al. Galactosylation of IgG associated oligosaccharides: reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity. Lancet. 1(8592), 966\u20139 (1988 Apr 30).","DOI":"10.1016\/S0140-6736(88)91781-3"},{"key":"59651_CR18","unstructured":"Pfeifle, R. et al. Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease. Nat. Immunol. Nature Publishing Group, 18(1), 104\u201313; (2017 Jan)."},{"key":"59651_CR19","doi-asserted-by":"crossref","unstructured":"Rook, G. A. et al. Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy. J. Autoimmun. 4(5), 779\u201394 (1991 Oct).","DOI":"10.1016\/0896-8411(91)90173-A"},{"issue":"6","key":"59651_CR20","doi-asserted-by":"publisher","first-page":"R193","DOI":"10.1186\/ar2892","volume":"11","author":"FE van de Geijn","year":"2009","unstructured":"van de Geijn, F. E. et al. Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. Arthritis Research & Therapy. Bio. Med. Central. 11(6), R193 (2009).","journal-title":"Arthritis Research & Therapy. Bio. Med. Central."},{"key":"59651_CR21","doi-asserted-by":"crossref","unstructured":"Bondt A. et al. Association between galactosylation of immunoglobulin G and improvement of rheumatoid arthritis during pregnancy is independent of sialylation. J. Proteome Res. 12(10), 4522\u201331 (2013 Oct 4).","DOI":"10.1021\/pr400589m"},{"key":"59651_CR22","doi-asserted-by":"crossref","unstructured":"Gi\u0144dzie\u0144ska-Sie\u015bkiewicz, E. et al. Changes of glycosylation of IgG in rheumatoid arthritis patients treated with methotrexate. Adv. Med. Sci. 61(2), 193\u20137 (2016 Sep).","DOI":"10.1016\/j.advms.2015.12.009"},{"key":"59651_CR23","doi-asserted-by":"crossref","unstructured":"Pasek, M. et al. Galactosylation of IgG from rheumatoid arthritis (RA) patients \u2013 changes during therapy. Glycoconjugate Journal. 23(7\u20138), 463\u201371 (2006 Nov).","DOI":"10.1007\/s10719-006-5409-0"},{"issue":"12","key":"59651_CR24","doi-asserted-by":"publisher","first-page":"e81448","DOI":"10.1371\/journal.pone.0081448","volume":"8","author":"S Ogata","year":"2013","unstructured":"Ogata, S. et al. Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G. Stover CM, editor. PLoS ONE. Public Library of Science 8(12), e81448 (2013).","journal-title":"PLoS ONE. Public Library of Science"},{"issue":"5","key":"59651_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/jcla.20191","volume":"21","author":"A Croce","year":"2007","unstructured":"Croce, A. et al. Effect of infliximab on the glycosylation of IgG of patients with rheumatoid arthritis. Journal of clinical laboratory analysis. 21(5), 303\u201314 (2007).","journal-title":"Journal of clinical laboratory analysis."},{"key":"59651_CR26","doi-asserted-by":"crossref","unstructured":"Van Beneden, K. et al. Reversible changes in serum immunoglobulin galactosylation during the immune response and treatment of inflammatory autoimmune arthritis. Ann. Rheum. Dis. BMJ Publishing Group Ltd; 68(8), 1360\u20135, (2009 Aug).","DOI":"10.1136\/ard.2008.089292"},{"key":"59651_CR27","doi-asserted-by":"crossref","unstructured":"Collins, E. S. et al. Glycosylation status of serum in inflammatory arthritis in response to anti-TNF treatment. Rheumatology (Oxford). 52(9), 1572\u201382 (2013 Sep).","DOI":"10.1093\/rheumatology\/ket189"},{"key":"59651_CR28","doi-asserted-by":"crossref","unstructured":"Zwaginga, J. J. et al. Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients. Haematologica. Haematologica; 100(3), e90\u20132 (2015 Mar).","DOI":"10.3324\/haematol.2014.110213"},{"key":"59651_CR29","doi-asserted-by":"crossref","unstructured":"Wuhrer, M. et al. Glycosylation profiling of immunoglobulin G (IgG) subclasses from human serum. Proteomics. 7(22), 4070\u201381 (2007 Nov).","DOI":"10.1002\/pmic.200700289"},{"issue":"16","key":"59651_CR30","first-page":"520","volume":"5","author":"G Vidarsson","year":"2014","unstructured":"Vidarsson, G., Dekkers, G. & Rispens, T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. Frontiers 5(16), 520 (2014).","journal-title":"Front Immunol. Frontiers"},{"key":"59651_CR31","doi-asserted-by":"crossref","unstructured":"Rodeghiero, F. et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. American Society of Hematology; 113(11), 2386\u201393 (2009 Mar 12).","DOI":"10.1182\/blood-2008-07-162503"},{"key":"59651_CR32","doi-asserted-by":"crossref","unstructured":"Nakao, H. et al. Hypogalactosylation of immunoglobulin G sugar chains and elevated serum interleukin 6 in Castleman\u2019s disease. Clin. Chim. Acta. 197(3), 221\u20138 (1991 Mar 29).","DOI":"10.1016\/0009-8981(91)90142-Y"},{"key":"59651_CR33","unstructured":"Cobb, B. A. The history of IgG glycosylation and where we are now. Glycobiology. 13(433\u2013443), 315\u201312 (2019 Aug 27)."},{"key":"59651_CR34","unstructured":"Zhipeng, S., Jingjing, G., Qing, X., Yanping, W. & Yunsen, L. Possible role of \u03b2-galactosidase in rheumatoid arthritis. Modern Rheumatology. Taylor & Francis, 0(0), 1\u201310, (2019)."},{"key":"59651_CR35","doi-asserted-by":"crossref","unstructured":"Arnold, D. M. et al. Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry. Blood Adv. 3rd ed. 1(25), 2414\u201320 (2017 Nov 28).","DOI":"10.1182\/bloodadvances.2017010942"},{"key":"59651_CR36","doi-asserted-by":"crossref","unstructured":"Cooper, N. et al. Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia. British Journal of Haematology. 158(4), 539\u201347 (2012 Aug).","DOI":"10.1111\/j.1365-2141.2012.09184.x"},{"key":"59651_CR37","doi-asserted-by":"crossref","unstructured":"Olsson, B. et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 9(9), 1123\u20134 (2003 Sep).","DOI":"10.1038\/nm921"},{"key":"59651_CR38","doi-asserted-by":"crossref","unstructured":"Qiu, J. et al. CD8(+) T cells induce platelet clearance in the liver via platelet desialylation in immune thrombocytopenia. Sci Rep. Nature Publishing Group;6, 27445\u201312 (2016 Jun 20).","DOI":"10.1038\/srep27445"},{"key":"59651_CR39","doi-asserted-by":"crossref","unstructured":"Maloney, D. G. et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood. 90(6), 2188\u201395 (1997 Sep 15).","DOI":"10.1182\/blood.V90.6.2188.2188_2188_2195"},{"key":"59651_CR40","doi-asserted-by":"crossref","unstructured":"Maloney, D. G. et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 84(8), 2457\u201366 (1994 Oct 15).","DOI":"10.1182\/blood.V84.8.2457.bloodjournal8482457"},{"key":"59651_CR41","doi-asserted-by":"crossref","unstructured":"Kapur, R. et al. A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy. Blood. 123(4), 471\u201380 (2014 Jan 23).","DOI":"10.1182\/blood-2013-09-527978"},{"key":"59651_CR42","doi-asserted-by":"crossref","unstructured":"Kapur, R. et al. Prophylactic anti-D preparations display variable decreases in Fc-fucosylation of anti-D. Transfusion. Wiley\/Blackwell (10.1111); 55(3), 553\u201362 (2014 Sep 19).","DOI":"10.1111\/trf.12880"},{"key":"59651_CR43","doi-asserted-by":"crossref","unstructured":"Sonneveld, M. E. et al. Glycosylation pattern of anti-platelet IgG is stable during pregnancy and predicts clinical outcome in alloimmune thrombocytopenia. British Journal of Haematology. 174(2), 310\u201320 (2016 Jul).","DOI":"10.1111\/bjh.14053"},{"key":"59651_CR44","doi-asserted-by":"crossref","unstructured":"Kapur, R. et al. Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn. British Journal of Haematology. 166(6), 936\u201345 (2014 Sep).","DOI":"10.1111\/bjh.12965"},{"key":"59651_CR45","doi-asserted-by":"crossref","unstructured":"Khellaf, M. et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood. 124(22), 3228\u201336 (2014 Nov 20).","DOI":"10.1182\/blood-2014-06-582346"},{"key":"59651_CR46","doi-asserted-by":"crossref","unstructured":"Marco, H. et al. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord. Bio. Med. Central. 15(1), 178 (2014 May 25).","DOI":"10.1186\/1471-2474-15-178"},{"key":"59651_CR47","doi-asserted-by":"crossref","unstructured":"Stasi R. et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 110(8), 2924\u201330 (2007 Oct 15).","DOI":"10.1182\/blood-2007-02-068999"},{"key":"59651_CR48","doi-asserted-by":"crossref","unstructured":"Gudbrandsdottir, S., Brimnes, M., K\u00f8llgaard, T., Hasselbalch, H. C. & Nielsen, C. H. Effects of rituximab and dexamethasone on regulatory and proinflammatory B-cell subsets in patients with primary immune thrombocytopenia. Eur J Haematol. 100(1), 45\u201352 (2018 Jan).","DOI":"10.1111\/ejh.12978"},{"key":"59651_CR49","doi-asserted-by":"crossref","unstructured":"Falck, D, Jansen, B. C., de Haan, N. & Wuhrer, M. High-Throughput Analysis of IgG Fc Glycopeptides by LC-MS. Methods Mol Biol. New York, NY: Springer New York; 1503(Suppl 1), 31\u201347 (2017).","DOI":"10.1007\/978-1-4939-6493-2_4"},{"key":"59651_CR50","doi-asserted-by":"crossref","unstructured":"Selman, M. H. J. et al. Fc specific IgG glycosylation profiling by robust nano-reverse phase HPLC-MS using a sheath-flow ESI sprayer interface. Journal of Proteomics. 75(4), 1318\u201329 (2012 Feb 2).","DOI":"10.1016\/j.jprot.2011.11.003"},{"key":"59651_CR51","doi-asserted-by":"crossref","unstructured":"Jansen, B. C. et al. LaCyTools: A Targeted Liquid Chromatography-Mass Spectrometry Data Processing Package for Relative Quantitation of Glycopeptides. J. Proteome Res. 15(7), 2198\u2013210 (2016 Jul 1).","DOI":"10.1021\/acs.jproteome.6b00171"},{"key":"59651_CR52","doi-asserted-by":"crossref","unstructured":"Bakovi\u0107, M. P. et al. High-throughput IgG Fc N-glycosylation profiling by mass spectrometry of glycopeptides. J. Proteome Res. 12(2), 821\u201331 (2013 Feb 1).","DOI":"10.1021\/pr300887z"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-59651-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-59651-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-59651-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T07:27:51Z","timestamp":1670311671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-59651-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,20]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["59651"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-59651-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,20]]},"assertion":[{"value":"10 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3051"}}